FDA's Letter to Heron Therapeutics (HRTX) Over Sustol Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
FDA Approval of Heron Therapeutics' (HRTX) Sustol Removes Major Overhang - Analyst
August 10, 2016 11:14 AM EDTLeerink affirms Heron Therapeutics (Nasdaq: HRTX) at Outperform with a price target of $33 following FDA approval of Sustol for treatment of chemo induced nausea and vomiting.
Analyst Jason Gerberry commented today: We are still reviewing the package insert, but Sustol... More
Pre-Open Stock Movers 08/10: (CLNE) (OCN) (HRTX) (YELP) Higher; (GEVO) (SPWR) (MYGN) (PRGO) Lower (more...)
August 10, 2016 9:28 AM EDTToday's Pre-Open Stock Movers
Gevo (NASDAQ: GEVO) 30% LOWER; reported Q2 EPS of ($0.15), versus ($0.66) reported last year. Revenue for the quarter came in at $8.11 million, versus $8.9 million reported last year.
SunPower (NASDAQ: SPWR) 30% LOWER; reported Q2 EPS of ($0.22), $0.02 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $420.5 million versus the consensus estimate of $345.08 million. GUIDANCE:... More
Heron Therapeutics (HRTX) Reports FDA Approval of SUSTOL
August 10, 2016 8:33 AM EDTHeron Therapeutics, Inc. (Nasdaq: HRTX) announced that the U.S. Food and Drug Administration (FDA) has approved SUSTOL® (granisetron) extended-release injection. SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.
SUSTOL is an extended-release, injectable 5-HT3 receptor antagonist that utilizes Herons Biochronomer® polymer-based drug delivery technology to maintain therapeutic levels of granisetron for 5 days, covering both the acute and... More
Heron Therapeutics (HRTX) Halted, News Pending
August 10, 2016 8:25 AM EDTHeron Therapeutics (NASDAQ: HRTX) Halted, News Pending
... More